Management of the metabolic effects of HIV and HIV drugs

Nature Reviews Endocrinology

Volumn 8, Issue 1, 2012, Pages 11-21

  Brown, Todd T ^a   Glesby, Marshall J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EFAVIRENZ; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; RECOMBINANT LEPTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAXAGLIPTIN; STAVUDINE; TENOFOVIR DISOPROXIL; TESAMORELIN; TESTOSTERONE; UNINDEXED DRUG; URIDINE; ZIDOVUDINE;

ADIPOSE TISSUE; AGING; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CHOICE; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPOATROPHY; LIPOHYPERTROPHY; LIPOSUCTION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SEX DIFFERENCE; TREATMENT OUTCOME; WAIST HIP RATIO;

ADIPOSE TISSUE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES;

EID: 83555164713     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.151     Document Type: Review

References (170)

1. Palella, F. J. Jr et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860 (1998).
2. Detels, R. et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280, 1497-1503 (1998).
3. Carr, A., Samaras, K., Chisholm, D. J. & Cooper, D. A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881-1883 (1998).
4. Lichtenstein, K. A. et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 32, 48-56 (2003).
5. Jacobson, D. L. et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin. Infect. Dis. 40, 1837-1845 (2005).
6. Tien, P. C. & Grunfeld, C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr. Opin. Infect. Dis. 17, 27-32 (2004).
7. Miller, J. et al. HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. HIV Med. 4, 293-301 (2003).
8. Santos, C. P. et al. Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors. AIDS 19 (Suppl. 4), S14-S21 (2005).
9. Mynarcik, D. C., McNurlan, M. A., Steigbigel, R. T., Fuhrer, J. & Gelato, M. C. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J. Acquir. Immune Defic. Syndr. 25, 312-321 (2000).
10. Wohl, D. et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J. Acquir. Immune Defic. Syndr. 48, 44-52 (2008).
11. Vigouroux, C. et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 17, 1503-1511 (2003).
12. Bogner, J. R. et al. Stavudine versus zidovudine and the development of lipodystrophy. J. Acquir. Immune Defic. Syndr. 27, 237-244 (2001).
13. Cherry, C. L. et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 42, 435-440 (2006).
14. Dubé, M. P. et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 1807-1818 (2005).
15. Haubrich, R. H. et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23, 1109-1118 (2009).
16. McComsey, G. et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: A prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 Infection [abstract 106LB]. Presented at the Proceedings of the 17th Conference on Retroviruses & Opportunistic Infections. CROI. San Francisco. February 16-19 (2010).
17. Lennox, J. L. et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55, 39-48 (2010).
18. Drechsler, H. & Powderly, W. G. Switching effective antiretroviral therapy: A review. Clin. Infect. Dis. 35, 1219-1230 (2002).
19. Hulgan, T. et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25, 37-47 (2011).
20. Montes, A. H. et al. The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS 24, 2499-2506 (2010).
21. Martin, A. et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 18, 1029-1036 (2004).
22. McComsey, G. A. et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin. Infect. Dis. 38, 263-270 (2004).
23. Moyle, G. J. et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20, 2043-2050 (2006).
24. Easterbrook, P. J. et al. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 9, 47-56 (2008).
25. Moyle, G. J. et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20, 2043-2050 (2006).
26. Martin, A. et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 18, 1029-1036 (2004).
27. Adams, M. et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100, 3149-3153 (1997).
28. Arioglu, E. et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. 133, 263-274 (2000).
29. Caron, M. et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50, 1378-1388 (2001).
30. Hadigan, C. et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. Ann. Intern. Med. 140, 786-794 (2004).
31. Carr, A. et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 363, 429-438 (2004).
32. Sutinen, J. et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir. Ther. 8, 199-207 (2003).
33. Mulligan, K. et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21, 47-57 (2007).
34. Schindler, K. et al. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in HIV-positive patients on highly-active antiretroviral therapy (HAART). Horm. Metab. Res. 41, 573-579 (2009).
35. Raboud, J. M. et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin. Trials 11, 39-50 (2010).
36. Slama, L. et al. Effect of pioglitazone on HIV-1-related lipodystrophy: A randomized double-blind placebo-controlled trial (ANRS 113). Antivir. Ther. 13, 67-76 (2008).
37. Domingo, P. et al. Uridine metabolism in HIV-1-infected patients: Effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. Plos ONE 5, e13896 (2010).
38. Walker, U. A. et al. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir. Ther. 8, 463-470 (2003).
39. Sutinen, J. et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: A randomized, double-blind, placebo-controlled trial. Antivir. Ther. 12, 97-105 (2007).
40. Calmy, A. et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: A randomized trial. HIV Med. 11, 493-501 (2010).
41. McComsey, G. A. et al. Uridine supplementation in the treatment of HIV lipoatrophy: Results of ACTG 5229. AIDS 24, 2507-2515 (2010).
42. Mallon, P. W. et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 20, 1003-1010 (2006).
43. Macallan, D. C. et al. Treatment of altered body composition in HIV-associated lipodystrophy: Comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin. Trials 9, 254-268 (2008).
44. Moyle, G. J., Brown, S., Lysakova, L. & Barton, S. E. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 7, 181-185 (2006).
45. Carey, D. L. et al. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J. Acquir. Immune Defic. Syndr. 46, 581-589 (2007).
46. Loutfy, M. R. et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 21, 1147-1155 (2007).
47. Guaraldi, G. et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 25, 1-12 (2011).
48. Guaraldi, G. et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin. Infect. Dis. 40, e13-e15 (2005).
49. Magkos, F. et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: A pilot study. Metabolism 60, 1045-1049 (2011).
50. Mulligan, K. et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J. Clin. Endocrinol. Metab. 94, 1137-1144 (2009).
51. Oral, E. A. et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570-578 (2002).
52. Torriani, M., Hadigan, C., Jensen, M. E. & Grinspoon, S. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J. Appl. Physiol. 95, 1005-1010 (2003).
53. Lo, J. et al. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS 24, 2127-2130 (2010).
54. Villarroya, F., Domingo, P. & Giralt, M. Lipodystrophy in HIV 1-infected patients: Lessons for obesity research. Int. J. Obes. (Lond.) 31, 1763-1776 (2007).
55. Grunfeld, C. et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J. Acquir. Immune Defic. Syndr. 45, 286-297 (2007).
56. Falutz, J. et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19, 1279-1287 (2005).
57. Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23, 469-480 (2006).
58. McComsey, G. A. et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin. Infect. Dis. 53, 185-196 (2011).
59. Sekhar, R. V. et al. Metabolic basis of HIV-lipodystrophy syndrome. Am. J. Physiol. Endocrinol. Metab. 283, E332-E337 (2002).
60. Sutinen, J. et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 47, 1668-1671 (2004).
61. Koutkia, P., Canavan, B., Breu, J. & Grinspoon, S. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J. Clin. Endocrinol. Metab. 90, 32-38 (2005).
62. Koutkia, P., Meininger, G., Canavan, B., Breu, J. & Grinspoon, S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 286, E296-E303 (2004).
63. Rietschel, P. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. 86, 504-510 (2001).
64. Guallar, J. P. et al. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS 22, 575-584 (2008).
65. Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364, 937-952 (2004).
66. Meisinger, C., Döring, A., Thorand, B., Heier, M. & Löwel, H. Body fat distribution and risk of type 2 diabetes in the general population: Are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am. J. Clin. Nutr. 84, 483-489 (2006).
67. Hadigan, C. et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32, 130-139 (2001).
68. Ammassari, A. et al. Relationship between HAART adherence and adipose tissue alterations. J. Acquir. Immune Defic. Syndr. 31 (Suppl. 3), S140-S144 (2002).
69. Reynolds, N. R., Neidig, J. L., Wu, A. W., Gifford, A. L. & Holmes, W. C. Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care 18, 663-673 (2006).
70. Blanch, J. et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin. Infect. Dis. 38, 1464-1470 (2004).
71. Scherzer, R. et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 25, 1405-1414 (2011).
72. Huang, J. S., Rietschel, P., Hadigan, C. M., Rosenthal, D. I. & Grinspoon, S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 15, 975-982 (2001).
73. Tien, P. C. et al. Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J. Aquir. Immune Defic. Syndr. 48, 169-176 (2008).
74. Ryan, P. et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med. 10, 53-59 (2009).
75. Stanley, T. L. et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 23, 1349-1357 (2009).
76. Thöni, G. J. et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab. 28, 397-404 (2002).
77. Dolan, S. E. et al. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: A randomized trial. Arch. Intern. Med. 166, 1225-1231 (2006).
78. Fitch, K. V. et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20, 1843-1850 (2006).
79. Hadigan, C. et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284, 472-477 (2000).
80. Kohli, R., Shevitz, A., Gorbach, S. & Wanke, C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med. 8, 420-426 (2007).
81. Sheth, S. H. & Larson, R. J. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: A meta-analysis of randomized trials. BMC Infect. Dis. 10, 183 (2010).
82. Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H. & Sannerstedt, R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39, 897-901 (1990).
83. Rietschel, P. et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. CID 31, 1240-1244 (2000).
84. Wunder, D. M. et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir. Ther. 12, 261-265 (2007).
85. Bhasin, S. et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J. Clin. Endocrinol. Metab. 92, 1049-1057 (2007).
86. Schambelan, M. et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann. Intern. Med. 125, 873-882 (1996).
87. Kotler, D. P. et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35, 239-252 (2004).
88. Kotler, D. P. et al. Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J. Acquir. Immune Defic. Syndr. 43, 378-380 (2006).
89. Luzi, L. et al. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: A randomized placebo-controlled study. Eur. J. Endocrinol. 153, 781-789 (2005).
90. Hansen, B. R. et al. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 11, 266-275 (2010).
91. Lo, J. et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial. JAMA 300, 509-519 (2008).
92. Lo, J., You, S. M., Liebau, J., Lee, H. & Grinspoon, S. Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA 304, 272-274 (2010).
93. Falutz, J. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359-2370 (2007).
94. Falutz, J. et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. J. Acquir. Immune Defic. Syndr. 53, 311-322 (2010).
95. Falutz, J. et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metab. 95, 4291-4304 (2010).
96. Renehan, A. G. et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 363, 1346-1353 (2004).
97. Clayton, P. E., Banerjee, I., Murray, P. G. & Renehan, A. G. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat. Rev. Endocrinol. 7, 11-24 (2011).
98. Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370, 59-67 (2007).
99. Grunfeld, C. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045-1052 (1992).
100. Feingold, K. R. et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76, 1423-1427 (1993).
101. Tien, P. C. et al. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 24, 2809-2817 (2010).
102. Baker, J. et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J. Infect. Dis. 201, 285-292 (2010).
103. Riddler, S. A. et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289, 2978-2982 (2003).
104. Shafran, S. D., Mashinter, L. D. & Roberts, S. E. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6, 421-425 (2005).
105. Lee, G. A. et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18, 641-649 (2004).
106. Shikuma, C. M. et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J. Acquir. Immune Defic. Syndr. 44, 540-550 (2007).
107. van Leth, F. et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 1, e19 (2004).
108. Tungsiripat, M. et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24, 1781-1784 (2010).
109. Dubé, M. P. et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37, 613-627 (2003).
110. [No authors listed] Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
111. Law, M. G. et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med. 7, 218-230 (2006).
112. Friis-Møller, N. et al. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. Eur. J. Cardiovasc. Prev. Rehabil. 17, 491-501 (2010).
113. Gatell, J. et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin. Infect. Dis. 44, 1484-1492 (2007).
114. Parienti, J. J., Massari, V., Rey, D., Poubeau, P. & Verdon, R. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: A randomized, controlled study. Clin. Infect. Dis. 45, 263-266 (2007).
115. Eron, J. J. et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 375, 396-407 (2010).
116. Martínez, E. et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 24, 1697-1707 (2010).
117. Fisac, C. et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19, 917-925 (2005).
118. Calza, L. et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19, 1051-1058 (2005).
119. Silverberg, M. J. et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Intern. Med. 150, 301-313 (2009).
120. Aberg, J. A. et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res. Hum. Retroviruses 21, 757-767 (2005).
121. Dubé, M. P. et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir. Ther. 11, 1081-1089 (2006).
122. Gerber, J. G. et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186. J. Acquir. Immune Defic. Syndr. 47, 459-466 (2008).
123. Gerber, M. T. et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39, 419-425 (2004).
124. Wohl, D. A. et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41, 1498-1504 (2005).
125. Miller, J. et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16, 2195-2200 (2002).
126. Aslangul, E. et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: A randomized trial. AIDS 24, 77-83 (2010).
127. Moyle, G. J. et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15, 1503-1508 (2001).
128. Henry, K., Melroe, H., Huebsch, J., Hermundson, J. & Simpson, J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352, 1031-1032 (1998).
129. Fichtenbaum, C. J. et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569-577 (2002).
130. Sekar, V. J. et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract 55]. Program and Abstracts of the 8th International Workshop on Pharmacology of HIV Therapy, Budapest, Hungary, April 16-18 (2007).
131. Prezista® (darunavir) package insert (Tibotec, Raritan, NJ, 2009).
132. Kiser, J. J. et al. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Defic. Syndr. 47, 570-578 (2008).
133. Hsyu, P. H., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H. & Kerr, B. M. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. 45, 3445-3450 (2001).
134. Gerber, J. G. et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39, 307-312 (2005).
135. Brown, T. T. et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179-1184 (2005).
136. Bastard, J. P. et al. High incidence and risk factors for diabetes over 9-year follow-up after first generation protease inhibitor initiation in the ARNS CO8 APROCO-COPILOTE cohort. Antivir. Ther. 14 (Suppl. 2), A5 (2009).
137. Grunfeld, C. Insulin resistance in HIV infection: Drugs, host responses, or restoration to health? Top. HIV Med. 16, 89-93 (2008).
138. Blümer, R. M. et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 22, 227-236 (2008).
139. Fleischman, A. et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function inmuscle of healthy adults. Am. J. Physiol. Endocrinol. Metab. 292, E1666-E1673 (2007).
140. Brown, T. T. et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 19, 1375-1383 (2005).
141. Brown, T. T., Tassiopoulos, K., Bosch, R. J., Shikuma, C. & McComsey, G. A. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 33, 2244-2249 (2010).
142. Schambelan, M. et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J. Acquir. Immune Defic. Syndr. 31, 257-275 (2002).
143. Wohl, D. A. et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis. 43, 645-653 (2006).
144. [No authors listed] Diagnosis and classification of diabetes mellitus. Diabetes Care 34 (Suppl. 1), S62-S69 (2011).
145. Diop, M. E. et al. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res. Hum. Retroviruses 22, 1242-1247 (2006).
146. Kim, P. S. et al. A1C underestimates glycemia in HIV Infection. Diabetes Care 32, 1591-1593 (2009).
147. Glesby, M. J. et al. Glycated haemoglobin in diabetic women with and without HIV infection: Data from the Women's Interagency HIV Study. Antivir. Ther. 15, 571-577 (2010).
148. Fitch, K. V. et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20, 1843-1850 (2006).
149. Hadigan, C., Rabe, J. & Grinspoon, S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 87, 4611-4615 (2002).
150. Derosa, G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs 70, 1945-1961 (2010).
151. Brown, T. T. & Qaqish, R. B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 20, 2165-2174 (2006).
152. Triant, V. A., Brown, T. T., Lee, H. & Grinspoon, S. K. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J. Clin. Endocrinol. Metab. 93, 3499-3504 (2008).
153. Nathan, D. M. et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care 30, 753-759 (2007).
154. Triant, V. A., Lee, H., Hadigan, C. & Grinspoon, S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506-2512 (2007).
155. Worm, S. W. et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201, 318-330 (2010).
156. Triant, V. A., Meigs, J. B. & Grinspoon, S. K. Association of C-reactive protein and HIV infection with acute myocardial infarction. J. Acquir. Immune Defic. Syndr. 51, 268-273 (2009).
157. Triant, V. A. et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J. Acquir. Immune Defic. Syndr. 55, 615-619 (2010).
158. Ribaudo, H. J. et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. Clin. Infect. Dis. 52, 929-940 (2011).
159. Costagliola, D., Lang, S., Mary-Krause, M. & Boccara, F. Abacavir and cardiovascular risk: Reviewing the evidence. Curr. HIV/AIDS Rep. 7, 127-133 (2010).
160. Lichtenstein, K. et al. Analysis of cardiovascular risk factors in the HIV Outpatient Study Cohort (HOPS). In the Program and Abstracts of the 13th Conference of Retroviruses and Opportunistic Infections, 735 February 5-8 (2006).
161. Fuster, M. et al. Smoking cessation in HIV patients: Rate of success and associated factors. HIV Med. 10, 614-619 (2009).
162. Petoumenos, K. et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study(*). HIV Med. 12, 412-421 (2011).
163. Seaberg, E. C. et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19, 953-960 (2005).
164. Chobanian, A. V. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
165. [No authors listed] Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 150, 396-404 (2009).
166. Hunt, P. W. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008).
167. French, M. A., King, M. S., Tschampa, J. M., da Silva, B. A. & Landay, A. L. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J. Infect. Dis. 200, 1212-1215 (2009).
168. Shikuma, C. M. et al. Change in high-sensitivity c-reactive protein
169. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
170. Deeks, S. G. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top. HIV Med. 17, 118-123 (2009).